Quanterix Corp (NASDAQ:QTRX) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus target price of $25.67 for the company and are forecasting that the company will post ($0.30) earnings per share for the current quarter, according to Zacks. Zacks has also given Quanterix an industry rank of 187 out of 265 based on the ratings given to its competitors.
Several research analysts have recently issued reports on QTRX shares. BTIG Research started coverage on Quanterix in a research note on Tuesday, January 2nd. They set a “buy” rating and a $26.00 price target for the company. Leerink Swann started coverage on Quanterix in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $27.00 price target for the company. Cowen started coverage on Quanterix in a research note on Tuesday, January 2nd. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. started coverage on Quanterix in a research note on Tuesday, January 2nd. They set an “overweight” rating for the company.
Quanterix (NASDAQ:QTRX) traded down $0.12 during trading hours on Friday, hitting $20.94. The stock had a trading volume of 93,993 shares, compared to its average volume of 116,926. Quanterix has a fifty-two week low of $15.56 and a fifty-two week high of $23.70.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.com-unik.info/2018/01/20/brokerages-anticipate-quanterix-corp-qtrx-to-announce-0-30-eps.html.
Quanterix Company Profile
Quanterix Corporation is a United States-based company, which develops tools for high definition diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.